Citations

Clear

6273 citation(s) found for "To, Andrew".

Abstract P6-07-03: An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome mate-pair sequencing data
Asmann, Yan W. , Necela, Brian M. , Chen, Xianfeng , Kocher, Jean‐Pierre , Novak, Anne J. , Perez, Edith A. , Thompson, E. Aubrey , Wang, Chen , Maurer, Matthew J. , Habermann, Thomas M. , Slager, Susan L. , Feldman, Andrew L. , Cerhan, James R.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 75 | Issue: 9_Supplement | Pages: P6-07-03-P6-07-03

10.1158/1538-7445.sabcs14-p6-07-03 Get It

Abstract Objectives and Rationale: Structural variants (SV) including large copy number aberrations (CNV), translocations, inversions, and large insertions and deletions (INDEL) play a critical role in tumorigenesis and progression. In fact, we now know that tumors can be categorized according to the size of mutations harbored. In several cancers, including ovarian and breast cancer, the large structural mutations, rather than single site mutations, play a dominate role in tumor etiology. Therefore, it's critical to implement reliable algorithm for the detection of structural variants in DNA sequencing data. Mate-pair sequencing is a protocol specifically implemented for detection of the whole-genome level structural variants. It requires less sequencing depth therefor is cost effective, and enables the detection of CNVs, translocations, and inversions simultaneously. However, so far there has been no reliable bioinformatics pipeline for the analyses of the mate-pair sequencing data. Methods: Our novel algorithm, the SnowShoes-SV, is an exhaustive search algorithm designed specifically for mate-pair DNA sequencing data analyses. It calls the SVs based on disconcordant read pairs. The false SVs are filtered according to the following criteria: (i) the number of the supporting read pairs; (ii) the lack of reads from control data that implicate SV at the same region; (iii) the mappability and uniqueness of the region based on data from the ENCODE project; (iv) consistencies of the mapping orientations of the supporting read pairs; (v) the similar sizes between sequencing library and the two end read clusters. Results: Using a set of samples previously genotyped by aCGH, the SnowShoes-SV successfully detected all known CNVs and other SVs. It also identified copy number neutral translocations and inversions previously not identified by aCGH. In addition, the algorithm nominated novel SVs which are to be validated by PCR. Conclusions: SnowShoes-SV is a highly sensitive and specific algorithm for SV detection from the mate-pair DNA sequencing data. Citation Format: Yan W Asmann, Chen Wang, Brian M Necela, Xianfeng Chen, Jean-Pierre A Kocher, Matthew J Maurer, Thomas M Habermann, Susan L Slager, Andrew L Feldman, Anne J Novak, James R Cerhan, Edith A Perez, E Aubrey Thompson. An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome mate-pair sequencing data [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-07-03.
Abstract P4-12-03: Triple-negative breast cancer: Frequency of inherited mutations in breast cancer susceptibility genes
Miron, Penelope , Olswold, Curtis, Guidugli, Lucia, Beckmann, Matthias W. , Rack, Brigitte , Ekici, Arif B. , Slager, Susan L., Vachon, Celine M. , Eccles, Diana M, Fasching, Peter A. , Couch, Fergus J. , Hart, Steven N. , Sharma, Priyanka , Toland, Amanda Ewart , Olson, Janet E. , Godwin, Andrew K. , Pankratz, V. Shane , Slettedahl, Seth W. , Konstantopoulou, Irene , Fostira, Florentia , Fountzilas, George , Pelttari, Liisa M. , Yao, Song , Garber, Judy E. , Cox, Angela , Brauch, Hiltrud , Ambrosone, Christine B. , Nevanlinna, Heli , Yannoukakos, Drakoulis , Vachon, Celine M. , Eccles, Diana M, Ekici, Arif B

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 75 | Issue: 9_Supplement | Pages: P4-12-03-P4-12-03

10.1158/1538-7445.sabcs14-p4-12-03 Get It

Abstract Background: Guidelines recommend germline mutation testing of breast cancer predisposition genes in triple negative (TN) breast cancer cases with a family history of breast or ovarian cancer or when diagnosed under age 60. However, the prevalence of mutations in these genes among TN cases unselected for family history of breast or ovarian cancer is not known. Methods: To assess the frequency of mutations in 16 predisposition genes in TN cases we screened a large cohort of TN patients (n=1824) unselected for family history of breast or ovarian cancer from 12 centers and 824 study matched unaffected controls for mutations using a panel-based sequencing approach. Results: Deleterious mutations were identified in 15% of TN patients: 8.5% had BRCA1, 2.7% had BRCA2, and 3.6% had mutations in 12 other genes. Mutations in non-BRCA1/2 genes encoding proteins implicated in homologous recombination repair of DNA double strand breaks were detected at the same frequency as in breast cancer families. TN cases with mutations had high-grade tumors and were diagnosed at an earlier age than non-mutated cases. However, 10% of TN cases diagnosed at ≥60 years and 5% with no family history of cancer were also found to carry mutations. Inactivating mutations in non-BRCA1/2 predisposition genes were associated with moderate to high risks of TN breast cancer. Conclusions: National Comprehensive Cancer Network (NCCN) guidelines support clinical genetic testing of breast cancer predisposition genes in 95% of TN breast cancer patients carrying mutations in susceptibility genes. In contrast, National Institute of Health and Care Excellence (NICE) guidelines in the U.K. do not support genetic testing of a substantial proportion of TN patients with predisposing alleles. Frequency tables for inherited mutations in known predisposition genes based on age of diagnosis and family history of cancer will allow for selection of TN patients most likely to carry mutations in the predisposition genes. Citation Format: Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Penelope Miron, Janet E Olson, Andrew Godwin, Vernon S Pankratz, Curtis Olswold, Seth Slettedahl, Lucia Guidugli, Matthias W Beckmann, Brigitte Rack, Arif B Ekici, Irene Konstantopoulou, Florentia Fostira, George Fountzilas, Liisa M Pelttari, Song Yao, Judy Garber, Angela Cox, Hiltrud Brauch, Christine Ambrosone, Heli Nevanlinna, Drakoulis Yannoukakos, Susan L Slager, Celine M Vachon, Diana M Eccles, Peter A Fasching. Triple-negative breast cancer: Frequency of inherited mutations in breast cancer susceptibility genes [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-12-03.
Abstract A26: Attacking the most downstream “gatekeeper,” the SIAH-dependent proteolytic machinery, in the oncogenic ERBB/K-RAS signaling pathway to block tumorigenesis and control metastasis in human cancer
Bian, Minglei, Zheleva, Vasilena, Urban, Zena M., Njogu, Monicah M., Odanga, Justin J. , Isbell, Andrew J., Perry, Roger R , Smyrk, Thomas C. , Petersen, Gloria M. , Liao, Yang , Hoefer, Richard A. , Tang, Amy

Mayo Clinic

Molecular Cancer Research | May 4, 2015 | Volume: 12 | Issue: 12_Supplement | Pages: A26-A26

10.1158/1557-3125.rasonc14-a26 Get It

Abstract Oncogenic K-RAS activation is a major menace that drives aggressive tumor progression and metastasis in 30% of all human cancer. Currently, there are no effective therapies to treat stage III and IV metastatic human cancers with oncogenic K-RAS hyperactivation that often confer drug resistance, aggressive tumor growth, systemic metastasis, and poor clinical outcome. Therefore, finding novel approaches and new drug targets to inhibit oncogenic K-RAS pathway activation is an urgent goal and the major challenge in cancer therapy and anti-K-RAS-based drug development. Instead of targeting an upstream signaling module such as EGFR/HER2/K-RAS/B-RAF, we targeted the most downstream signaling module in the oncogenic K-RAS signaling pathway called the SIAH-dependent proteolytic machinery. SIAHs are the human homologs of Seven-In-Absentia (SINA), an evolutionarily conserved RING E3 ligase - the most downstream signaling module and a critical “gatekeeper” required for proper RAS signal transduction. Guided by the insights and fundamental principles learned from the Drosophila RAS signal transduction, we conducted preclinical studies to dissect SIAH function in promoting the oncogenic K-RAS-driven tumorigenesis and metastasis in human cancer. We found that (1) SIAH is a new biomarker reflective of oncogenic K-RAS activation in human cancer, and (2) SIAH loss-of-function is highly effective to block tumorigenesis and metastasis against the well-established, end-stage and metastatic pancreatic cancer and triple negative breast cancer (TNBC). These findings demonstrate that SIAH is an attractive and logical new therapeutic target for developing novel and effective anti-K-RAS and anticancer therapy against metastatic human cancer. Through our work, SIAH has emerged as a promising new drug target against oncogenic K-RAS hyperactivation in metastatic human cancer cells. Using anti-SIAH molecules to block oncogenic K-RAS signaling in human cancer is an excellent example of science going “from the bench (basic research in fruit flies) to the bedside (preclinical studies and ultimately clinical trials)”. As a highly evolutionarily conserved E3 ligase that is the most downstream and the most conserved “signaling gatekeeper” in the oncogenic K-RAS signaling network, SIAH is uniquely and strategically positioned to become a great and logical anti-K-RAS drug target. Our preclinical studies have demonstrated that “SIAH-dependent proteolysis” is indeed an Achilles' heel in metastatic human cancer cells. Knowledge gained from our preclinical study has promising translational values. Anti-SIAH-based small molecule inhibitors are likely to aid in expanding our limited arsenal of novel anti-K-RAS-based anticancer therapies. By attacking the oncogenic K-RAS pathway using multi-pronged synergistic inhibitions at upstream (EGFR/HER2 membrane receptors), midstream (K-RAS/B-RAF/MEK/mTOR) and downstream (SIAH E3 ligase) signaling modules in parallel, we will be in a position to control the late-stage, relapsed and metastatic human cancers by shutting down the hyperactivated K-RAS signaling transduction cascades in cancer cells in the future. Citation Format: Minglei Bian, Yang Liao, Vasilena Zheleva, Zena Urban, Monicah Njogu, Justin J. Odanga, Andrew J. Isbell, Roger R. Perry, Richard A. Hoefer, Thomas C. Smyrk, Gloria M. Petersen, Amy H. Tang. Attacking the most downstream “gatekeeper,” the SIAH-dependent proteolytic machinery, in the oncogenic ERBB/K-RAS signaling pathway to block tumorigenesis and control metastasis in human cancer. [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr A26. doi: 10.1158/1557-3125.RASONC14-A26
Abstract LB-276: Prospective study of body mass index and adult weight change with colorectal cancer survival, overall and by tumor microsatellite instability status
Newton, Christina C. , Ahnen, Dennis J. , Farris, Alton B. , Figueiredo, Jane C. , Green, Roger C., McLaughlin, John, Phipps, Amanda I. , Renehan, Andrew G. , Win, Aung Ko , Lindor, Noralane M. , Campbell, Peter T. , Newcomb, Polly A. , Baron, John A. , Cleary, Sean P. , Cotterchio, Michelle , Marchand, Loı̈c Le , McLaughlin, John, Potter, John D. , Limburg, Paul J. , Win, Aung K , Farris, Alton B

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: LB-276-LB-276

10.1158/1538-7445.am2014-lb-276 Get It

Abstract Background: Tumor features such as stage, grade, and microsatellite instability (MSI) status have relevance for colorectal cancer survival whereas the prognostic role of body mass index (BMI) is unclear. We assessed the association of BMI and adult weight gain on colorectal cancer survival, overall and by strata of sex and MSI. Methods: Participants were identified from a multi-center cohort that includes 6,763 colorectal cancer patients with invasive colorectal cancer who were enrolled into the Colon Cancer Family Registry from 1997 to 2008. Vital status was updated through direct contact with patients/next-of-kin and/or linkage with mortality records. BMI 2 years before diagnosis, BMI at age 20 years, and adult weight gain were derived from self-reports of height and weight (i.e., weight 2 years before diagnosis and weight at age 20 years). Tumor MSI status was available for 4,987 patients. Multivariable, two-sided hazard ratios (HR) and 95% confidence intervals (CIs) were estimated from delayed-entry Cox proportional hazards models, controlling for age at diagnosis, TNM summary stage (i.e., I, II, III, IV or missing), smoking (current, former, never), and study center. Results: After a maximum of 13.7 years of follow-up from enrollment to end-of-study (median: 5.3 years), 2,335 patients had died. Higher BMI 2 years before cancer diagnosis (per 5-kg/m2) was associated with higher risk of all-cause mortality overall (HR, 1.10; 95% CI, 1.05 to 1.14), with similar associations when stratified by sex (men: HR, 1.07; 95% CI, 1.02 to 1.14; women: HR, 1.11: 95% CI, 1.05 to 1.17; p-interaction: 0.18) and MSI status (MS-stable/MSI-low: HR, 1.08; 95% CI, 1.03 to 1.14; MSI-high, HR: 1.19; 95% CI, 1.02 to 1.40; p-interaction: 0.88). In joint models, with MS-stable/MSI-low and normal BMI as the referent group, risk of death was lower for those with MSI-high and normal BMI (HR: 0.77; 95% CI: 0.59 to 1.00), higher for MS-stable/MSI-low and high (≥30) BMI (HR: 1.23; 95% CI: 1.07 to 1.42), and essentially the same for MSI-high and high BMI (HR: 0.97; 95% CI: 0.72 to 1.30). Similar patterns of association were observed for BMI at age 20 years and when the outcome was colorectal cancer-specific mortality, although not all associations remained statistically significant for some of the smaller sub-group analyses. After controlling for BMI at age 20 years, adult weight gain was only modestly associated with all-cause mortality (per 5 kg HR: 1.01; 95% CI: 1.00 to 1.02; p-trend: 0.07). Conclusion: High pre-diagnosis BMI was associated with increased mortality after colorectal cancer diagnosis; this association was consistent for men and women and by tumor MSI status. These results also suggest that obesity attenuates the survival advantage observed with MSI-high tumors. Citation Format: Peter T. Campbell, Christina Newton, Polly A. Newcomb, Dennis Ahnen, John Baron, Sean Cleary, Michelle Cotterchio, A. Brad Farris, Jane Figueiredo, Roger C. Green, Loic Le Marchand, John McLaughlin, Amanda Phipps, John D. Potter, Andrew Renehan, Aung Ko Win, Noralane Lindor, Paul Limburg. Prospective study of body mass index and adult weight change with colorectal cancer survival, overall and by tumor microsatellite instability status. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-276. doi:10.1158/1538-7445.AM2014-LB-276
Abstract CT339: Prospective molecular identification of ovarian cancer patients benefiting from PARP inhibitor (PARPi, rucaparib) maintenance therapy - reaching beyond germline BRCA mutations
Kaufmann, Scott H. , Allen, Andrew R., Raponi, Mitch , Giordano, Heidi, Maloney, Lara , Isaacson, Jeffrey D., Swisher, Elizabeth M. , McNeish, Iain A. , Coleman, Robert L. , Brenton, James D. , Ledermann, Jonathan A. , Kaufmann, Scott H

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: CT339-CT339

10.1158/1538-7445.am2014-ct339 Get It

Abstract Background: PARP inhibitors are thought to be effective therapy for cancers with homologous recombination (HR) deficiency, best shown to date in patients (pts) with a germline BRCA (gBRCA) mutation. The Cancer Genome Atlas (TCGA) estimated ∼ 50% of high-grade serous ovarian carcinoma (OC) pts have an HR defect (HRD) due to a BRCA mutation (germline or somatic), other HR gene mutation, or another mechanism, e.g., BRCA1 promoter methylation. A randomized maintenance trial of olaparib in recurrent OC demonstrated a clinical benefit in both gBRCA-mutated and gBRCA-wild-type pts. Currently, the best molecular predictors of PARPi response (other than a BRCA mutation) are not known. Platinum sensitivity, often used as a surrogate predictive indicator for PARPi response, is inadequate. A better technique, such as molecular analysis of tumor tissue, could be a superior method for selection of pts for PARPi therapy. Methods: The rucaparib development plan in OC employs a unique strategy of conducting the key trials in parallel, allowing the Phase 2 (ARIEL2) to complete first so that a molecular HRD signature, associated with sub-groups most likely to benefit, can be prospectively applied to the final analysis of the Phase 3 pivotal trial (ARIEL3). ARIEL2 is an ongoing, single-arm, open-label biomarker study designed to refine the molecular signature associated with a response to rucaparib. Eligible pts (n=180) have relapsed, platinum-sensitive, high-grade OC and measurable disease. All pts undergo a pre-dose biopsy and provide archival tumor tissue. Tumor tissue HR status is assessed using Foundation Medicine's next generation sequencing (NGS) platform and University of Washington's BROCA-HR panel, with the current HRD algorithm developed using in vitro/in vivo and TCGA (and similar) bioinformatic data. The key efficacy analyses to be correlated with tumor HR status are response by RECIST v1.1, GCIG-defined CA-125 response, and PFS. The number of gBRCA pts is limited to maximize non-gBRCA response predictors. Exploratory biomarkers include assessment of tissue NHEJ competency (candidate predictive biomarker) and circulating tumor DNA (candidate efficacy surrogate). The optimized algorithm will then be tested prospectively in ARIEL3 (n=540), an international, randomized (2:1), double-blind, placebo-controlled maintenance trial in platinum-sensitive OC in remission after platinum-based therapy. The primary endpoint of ARIEL3 is PFS in molecularly-defined HRD subgroups as determined by NGS analysis of archival tumor tissue using the optimized algorithm, refined (as required) through ARIEL2.Conclusion: This pair of clinical trials seeks to determine prospectively the appropriate population, among all women with platinum-sensitive OC, who derive a meaningful benefit from PARPi treatment in the maintenance setting. Citation Format: Elizabeth Swisher, Iain McNeish, Robert L. Coleman, James D. Brenton, Scott H. Kaufmann, Andrew Allen, Mitch Raponi, Heidi Giordano, Lara Maloney, Jeffrey Isaacson, Jonathan A. Ledermann. Prospective molecular identification of ovarian cancer patients benefiting from PARP inhibitor (PARPi, rucaparib) maintenance therapy - reaching beyond germline BRCA mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr CT339. doi:10.1158/1538-7445.AM2014-CT339
Abstract CT327: Multicenter phase I study of MRX34, a first-in-class microRNA miR-34 mimic liposomal injection
Beg, Muhammad Shaalan , Sachdev, Jasgit C. , Smith, Susan, Bader, Andres, Stoudemire, Jay, Kim, Sinil, Borad, Mitesh J. , Hong, David S. , Smith, Susan, Brenner, Andrew Jacob

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: CT327-CT327

10.1158/1538-7445.am2014-ct327 Get It

Abstract Background: MRX34 is a liposome-formulated double-stranded mimic of tumor suppressor microRNA-34 (miR-34), which is lost or expressed at reduced levels in many solid and hematologic malignancies. miR-34 functions in the p53 tumor suppressor pathway and regulates the expression of more than 20 cancer-related genes including BCL2, E2F3, HDAC1, MET, MEK1, CDK4/6, PDGFR-ɑ, SIRT1, WNT1/3, NOTCH-1, β-catenin, CD44, Nanog and AXL. miR-34 also suppresses stem-like properties in cancer cells and sensitizes cancer cells to cytotoxic and targeted therapies. A multicenter phase I clinical trial of MRX34 is being conducted in patients with unresectable hepatocellular carcinoma or metastatic cancer with liver involvement. Methods: Eligible patients are enrolled in a standard 3 + 3 dose escalation study at MRX34 starting dose of 10 mg/m2, administered IV on days 1, 4, 8, 11, 15, and 18 of 28-day cycles. Dexamethasone premedication was added after the first 2 dose levels. The primary objective is to determine the RP2D, and secondary objectives include assessments of safety, PK and objective response rate (ORR). Response is evaluated by CT/MRI every 8 weeks. Once RP2D has been established, expansion cohort will be treated at the RP2D, with specific focus on determining biological response in tumor biopsy material. The latter will include assessing tumor uptake of miR-34 mimic and down-regulation of target gene expression as was observed in animal models of cancer. Results: Twenty-five patients received study drug, and enrollment is currently ongoing at the 5th dose level (70 mg/m2) and MTD has not been reached. There were 18 Caucasians, 15 males, with a median age of 62.5 years and a median of 4 prior treatments. Liposomal formulation-associated infusion reactions have been observed as characterized by the following treatment emergent adverse events (AEs) out of 20 patients: fever (13), chills (12), fatigue (12), thrombocytopenia (8), diarrhea (8), back/flank pain (6), nausea (6), and neutropenia (4). Most common Gr 3/4 AEs were neutropenia (4), thrombocytopenia (3), fatigue (2), AST/ALT elevation (4) and back/flank pain (2). Addition of pre-dose dexamethasone with higher dose levels ameliorated infusion reactions. One patient died on study from disease progression. One dose-limiting toxicity was observed at the 2nd dose level (20 mg/m2; Gr 3 acute kidney injury associated with nausea, vomiting, diarrhea and dehydration) and one at the 5th dose level (70 mg/m2; Gr 3 increased AST). Conclusions: MRX34 has a manageable safety profile in patients with unresectable primary liver cancer or metastatic cancer with liver involvement. Determination of the R2PD, assessment of clinical response, and analyses of molecular markers are ongoing. Citation Format: Muhammad Shaalan Beg, Mitesh Borad, Jasgit Sachdev, David S. Hong, Susan Smith, Andres Bader, Jay Stoudemire, Sinil Kim, Andrew Brenner. Multicenter phase I study of MRX34, a first-in-class microRNA miR-34 mimic liposomal injection. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr CT327. doi:10.1158/1538-7445.AM2014-CT327
Abstract 3283: GWAS identifies risk variants for mucinous ovarian carcinoma
Kelemen, Linda E. , Phelan, Catherine M., Gayther, Simon A. , Goode, Ellen L. , Pearce, Celeste Leigh , Schildkraut, Joellen M. , Chenevix-Trench, Georiga, Goodman, Marc T. , Sellers, Thomas A. , Tyrer, Jonathan P. , Ramus, Susan J. , Berchuck, Andrew , Monteiro, Álvaro N.A. , Pharoah, Paul D.P. , Goodman, Marc T

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 3283-3283

10.1158/1538-7445.am2014-3283 Get It

Abstract Background Genome-wide association studies (GWAS) previously identified 8 new risk loci for all subtypes of epithelial ovarian carcinoma (EOC) and one specific to invasive serous EOC. One locus, at 2q31, was also associated with invasive mucinous EOC (mEOC) at P=7.3 x 10-7 (Nat Genet 2010:874). Here, we report new risk loci for mEOC, which is thought to develop from a borderline mucinous tumor. These loci may provide clues to the molecular basis of the disease. Methods We used genotype data from 4 GWAS of EOC and from multiple case-control studies in the Ovarian Cancer Association Consortium that had been genotyped using the iCOGS custom SNP panel (210k SNPs) developed for the Collaborative Oncological Gene-environment Study. We imputed genotypes of common variation across the genome using the 1000 Genomes Project reference panel and tested for association using log-additive unconditional regression models. Results Genotypes were available for 1,643 combined invasive and borderline mEOC and for 1,002 invasive-only mEOC of European ancestry. Three loci in new regions, and one locus in a previously published region, with minor allele frequency (MAF) > 1% and P ≤ 10-7 were found. The imputed SNP rs72831838 (imputation r2=0.67, MAF=0.15) is located at 2q13 in an intron of the PAX8 (paired box 8) gene (all mEOC OR=1.35, P=4.2 x 10-8 and invasive-only OR=1.43, P=9.6 x 10-8). PAX8 is a transcription factor and may be a Müllerian lineage marker that distinguishes carcinomas of gynecologic origin from other sites. The imputed variant at chr19:39745695 (imputation r2=0.61, MAF=0.32) is an insertion/deletion polymorphism located at 19q13.2 and falls within the MSRB1P1 (methionine sulfoxide reductase B1 pseudogene 1). This locus was associated with decreased risk (all mEOC OR=0.74, P = 2.1 x 10-9 and invasive-only OR=0.79, P = 8.1 x 10-5) and is enriched with the H3K27Ac histone mark that identifies active enhancers of gene expression. The imputed SNP rs6425050 (imputation r2=0.45, MAF=0.19) is located at 1q25 (all mEOC OR=1.38, P=4.7 x 10-8 and invasive-only OR=1.41, P=1.6x10-6). This SNP is intronic to PLA2G4A (phospholipase A2, group IVA), which encodes an enzyme that hydrolyzes membrane phospholipids for eicosanoid metabolism and signaling. None of these loci were associated with other EOC histological subtypes at P ≤ 10-7. The genotyped SNP, rs711830 (MAF=0.32), is located at 2q31.1 in the 3′ region of the HOXD3 homeobox gene (all mEOC OR=1.30, P=7.5 x 10-12 and invasive-only OR=1.26, P=7.8 x 10-7). This SNP is highly correlated (r2=0.99) with rs2072590, which is located 5.3kb upstream and previously reported by us to be associated with mEOC and invasive serous EOC (Nat Genet 2010:874). The HOXD3 locus is highly conserved and may also be a marker of Müllerian cell type origin. Conclusions The 3 new loci for mEOC require confirmation by genotyping. Fine mapping and functional analysis of all loci is needed in order to determine their likely target genes. Citation Format: Linda E. Kelemen, Jonathan Tyrer, Catherine M. Phelan, Susan J. Ramus, Andrew Berchuck, Simon A. Gayther, Ellen L. Goode, Celeste L. Pearce, Joellen M. Schildkraut, Georiga Chenevix-Trench, Alvaro N. Monteiro, Marc T. Goodman, Thomas A. Sellers, Paul PD Pharoah. GWAS identifies risk variants for mucinous ovarian carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3283. doi:10.1158/1538-7445.AM2014-3283
Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer
Carpenter, Jane, Severi, Gianluca , Fasching, Peter A. , Miron, Penelope , Chang‐Claude, Jenny , Kristensen, Vessela N. , Goodfellow, Paul J. , Sicotte, Hugues , Prodduturi, Naresh, Visscher, Daniel W., Eckel‐Passow, Jeanette E. , Anderson, S. Keith , Olswold, Curtis, Mannermaa, Arto, Hamann, Ute , Eccles, Diana M., Vachon, Celine M., Purrington, Kristen S. , Yannoukakos, Drakoulis , Nevanlinna, Heli , Cox, Angela , Ambrosone, Christine B. , Toland, Amanda Ewart , Godwin, Andrew K. , Brauch, Hiltrud , Martin, Nicholas G. , Montgomery, Grant W. , Anton‐Culver, Hoda , Olson, Janet E. , Slettedahl, Seth W. , Wang, Xianshu , Pankratz, V. Shane , Slager, Susan L. , Zheng, Wei , Mannermaa, Arto, Eccles, Diana M., Couch, Fergus J. , Severi, Gianluca

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 3266-3266

10.1158/1538-7445.am2014-3266 Get It

Abstract Recent studies have shown that associations between common genetic variation and gene expression in breast tumors provide insight into the functional mechanisms underlying breast cancer risk loci. However, the relationship between genetic variation, gene expression, and risk of triple negative (TN) breast cancer remains largely unexplored. We performed a genome-wide expression quantitative trait locus (eQTL) analysis of TN breast cancer using 668 formalin-fixed paraffin embedded TN tumors from the Triple Negative Breast Cancer Consortium (TNBCC) to identify novel genes relevant to TN breast cancer risk and to further explore the biology underlying known TN risk loci. Cis-eQTLs were defined as correlations between single nucleotide polymorphisms (SNP) and expression of genes within 1Mb, and trans-eQTLs were defined as the remainder of all SNP-gene correlations. In a genome-wide analysis, we identified 68,012 cis-eQTLs, representing correlations between 42,193 SNPs and 2,092 genes that were significant at a 10% false discovery rate (FDR). We also identified 70 trans-eQTLs across two unique genes at the same FDR threshold. Five cis-eQTLs involved SNPs previously associated with TN breast cancer risk (p<5.0x10-5) in 3,700 TN cases and 4,700 controls from the TNBCC. Three of these, located on chromosomes 5p (cis-eQTL p=4.8x10-34; risk p=1.1x10-7), 7p (cis-eQTL p=6.1x10-10; risk p=1.3x10-7), and 17q (cis-eQTL p=1.8x10-15; risk p=2.9x10-7), have previously been reported in public databases of normal tissue. The remaining two TN breast cancer cis-eQTLs, located on chromosomes 8q (cis-eQTL p=6.3x10-6, risk p=8.3x10-6) and 14q (cis-eQTL p=3.1x10-6, risk p=1.2x10-5), have not been reported as eQTLs in other tissues. In addition, 12 of 25 known TN breast cancer risk loci (PEX14, MDM4, 2q31.1, ESR1, 11q13.1, 11q24.3, 12p13.1, PTHLH, NTN4, 12q24, 19p13.1, MLK1), contained at least one significant cis-eQTL. In summary, we have identified five cis-eQTLs that may identify novel risk loci for TN breast cancer. Citation Format: Kristen S. Purrington, Drakoulis Yannoukakos, Jane Carpenter, Heli Nevanlinna, Angela Cox, Gianluca Severi, Christine Ambrosone, Amanda Ewart Toland, Andrew K. Godwin, Hiltrud Brauch, Peter A. Fasching, Penelope Miron, Jenny Chang-Claude, Nicholas G. Martin, Grant W. Montgomery, Vessela Kristensen, Hoda Anton-Culver, Paul Goodfellow, Janet E. Olson, Hugues Sicotte, Naresh Prodduturi, Daniel W. Visscher, Jeanette E. Eckel-Passow, S. Keith Anderson, Seth Slettedahl, Curtis Olswold, Xianshu Wang, V. Shane Pankratz, Susan Slager, Wei Zheng, Arto Mannermaa, Ute Hamann, Diana M. Eccles, Celine M. Vachon, Fergus J. Couch. Expression quantitative trait locus analysis of triple negative breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3266. doi:10.1158/1538-7445.AM2014-3266
Abstract 2323: Interferon regulatory factor-4 is transcriptionally regulated by NF-κB in peripheral T-cell lymphomas
Boddicker, Rebecca L., Kip, N. Sertac, Almada, Luciana L. , Porcher, Julie C., Grote, Deanna M., Ansell, Stephen M. , Fernández-Zapico, Martín E. , Luchtel, Rebecca A. , Feldman, Andrew L.

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 2323-2323

10.1158/1538-7445.am2014-2323 Get It

Abstract Interferon regulatory factor-4 (IRF4) is a tightly-regulated transcription factor involved in growth and differentiation of normal lymphocytes. IRF4 is expressed in multiple lymphoid malignancies and its expression drives tumor growth. Thus, characterization of the molecular events regulating IRF4 levels is key to design any targeting strategy. Here, we define a novel regulatory mechanism controlling IRF4 expression in peripheral T-cell lymphoma (PTCL), an aggressive non-Hodgkin lymphoma with poor overall survival rates and high levels of this transcription factor. In normal T cells, IRF4 was induced upon external activation of protein kinase C (PKC) by phorbol myristate acetate and ionomycin, an effect reversed by the PKC inhibitor, enzastaurin. Unlike normal T cells, PTCL cells constitutively expressed IRF4 in the absence of external stimulation, and this expression was resistant to enzastaurin. To identify regulators of IRF4 expression in PTCL, we performed a pharmacological screen using inhibitors that targeted PKC-associated pathways, including mitogen-activated protein kinases, PI3K/AKT/mTOR, and NF-κB. Of the inhibitors tested, only the proteasome inhibitor, bortezomib, showed a decrease in IRF4 expression in a dose- and time-dependent manner. To confirm this result we used a more specific NF-κB inhibitor blocking IκB kinase, BMS-345541. This inhibitor dramatically reduced IRF4 expression by 95.6% (P<0.0001). We used cell-based assays to investigate further the role of NF-κB in the transcriptional regulation of IRF4. A reporter assay for the IRF4 promoter demonstrated reduced promoter activity by siRNA knockdown of RelB and p52 NF-κB subunits to 31.4% and 36.9% of control (P=0.009). IRF4 promoter activity also was inhibited 67.9% by IκBαΔN, a dominant negative inhibitor of NF-κB activity (P=0.002), and was increased 71% by siRNA knockdown of IκBα (P<0.05). Chromatin immunoprecipitation assays confirmed the occupancy of NF-κB subunits in the IRF4 promoter, and this interaction was diminished in the presence of BMS-345541. Finally, knockdown of RelB and p52 subunits had a tendency to decrease IRF4 gene expression by 24.4% and 27.3% (P=0.1). Taken together, these data demonstrate transcriptional regulation of IRF4 by the NF-κB family in PTCL, and suggest the NF-κB pathway may represent a therapeutic target for PTCLs with concurrent IRF4 and NF-κB expression. Citation Format: Rebecca L. Boddicker, N. Sertac Kip, Luciana L. Almada, Julie C. Porcher, Deanna M. Grote, Stephen M. Ansell, Martin E. Fernandez-Zapico, Andrew L. Feldman. Interferon regulatory factor-4 is transcriptionally regulated by NF-κB in peripheral T-cell lymphomas. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2323. doi:10.1158/1538-7445.AM2014-2323
Abstract 1319: Vulnerability and resistance in glioblastoma to G2-specific drugs
Armstrong, Brock , Tran, Nhan L. , Dhruv, Harshil , Nelson, Andrew D. L. , Boerner, Julie L. , Sarkaria, Jann N. , Berens, Michael E. , Tran, Nhan L

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 1319-1319

10.1158/1538-7445.am2014-1319 Get It

Abstract Glioblastoma multiforme (GBM) is the most common and most lethal primary malignant brain tumor, affecting 25,000 patients per year. Approximately 87% of GBMs have abnormalities in the p53 pathway that affects G2 checkpoint. In the absence of p53, Wee1 kinase has been shown to regulate G2 checkpoint upon chemotherapeutic insult. Wee1 inhibits CDC2 function, thereby promoting G2 phase cell cycle arrest, thus preventing damaged cells from entering into premature mitosis without repairing the DNA. We hypothesize that in p53-deficient tumor cells, inhibitors of Wee1 would be effective to heighten DNA damage due to genetic and pharmacologic loss of both the G1 and G2 checkpoints, respectively. MK-1775 (Merck) is a potent and selective small molecule inhibitor of the Wee1 kinase that has demonstrated enhanced cytotoxic effect in combination with several chemotherapeutic agents in preclinical studies in vitro and in vivo. Here, we selected an array of short term cultures of glioma patient derived xenograft (PDX) models (GBM12, GBM43, GBM79, GBM84) and long term established glioma cell lines (U87, SF767, T98G) with aberrant and wild type G1 checkpoint pathways and investigated cytotoxic effects of MK-1775 as a single agent and in combination with Temozolomide (TMZ). Our results demonstrated differential sensitivity to MK-1775 and TMZ as single agents for different glioma cell lines in vitro. However, no correlation between MK-1775, TMZ sensitivity and p53 status of the cell lines was observed. Combination therapy with MK-1775 and TMZ showed a synergistic effect for one PDX model, GBM43, with combination index (CI) of 0.4. Combination therapy of all other glioma cell lines either showed an additive effect or antagonistic effect with CI of >0.75 irrespective of their p53 status. Our results demonstrated that synergistic effects of MK-1775 in combination with chemotherapy (TMZ) are not solely dependent on p53 status of glioma cells and require a more comprehensivce understanding of the molecular mechanism that dictates GBM's dependence on Wee1 for escaping DNA damage therapy. Supported by the Ben & Catherine Ivy Foundation Citation Format: Harshil D. Dhruv, Andrew D. Nelson, Brock Armstrong, Julie L. Boerner, Jann N. Sarkaria, Nhan L. Tran, Michael Berens. Vulnerability and resistance in glioblastoma to G2-specific drugs. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1319. doi:10.1158/1538-7445.AM2014-1319